Strategies for the management of rheumatoid arthritis

Orthopedics

Volumn 35, Issue 2, 2012, Pages 125-130

  Wilkie, W S ^a   Schwieterman, Philip ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOSTAMATINIB; GOLIMUMAB; HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ANAPHYLAXIS; ANTIBODY PRODUCTION; ASPERGILLOSIS; BIOLOGICAL THERAPY; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; FLUSHING; HISTOPLASMOSIS; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; LISTERIOSIS; LOADING DRUG DOSE; MONOTHERAPY; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OPPORTUNISTIC INFECTION; PAIN; PERIPHERAL EDEMA; PNEUMONIA; REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS;

EID: 84857480858     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20120123-36     Document Type: Review

References (28)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008; 58(1):15-25.
2. Harris ED Jr. Rheumatoid arthritis Pathophysiology and implications for therapy. N Engl J Med. 1990; 322:1277-1289.
3. Young A, Koduri G. Extraarticular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007; 21:907-927. (Pubitemid 47377809)
4. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. 1999; 26:1681-1685. (Pubitemid 29367305)
5. Pincus T, Kavanaugh A, Sokka T. Benefit/risk of therapies for rheumatoid arthritis:underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol. 2004; 22(5 suppl 35):S2-S11. (Pubitemid 39328350)
6. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Sys Pharmacy. 2006; 63:2451-2465. (Pubitemid 46391141)
7. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med. 1994; 330:1368-1375. (Pubitemid 24136062)
8. Nagashima M, Matsuoka T, Saitoh K, Koyama T, Kikuchi O, Yoshino S. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006; 24:260-267. (Pubitemid 44151144)
9. Feldmann M, Brennan FM, Mauni RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immuno. 1996; 14:397-440. (Pubitemid 26130190)
10. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999; 163:1521-1528. (Pubitemid 29352775)
11. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001; 344(14):1099-1100. (Pubitemid 32267986)
12. Remicade (Infliximab) package insert. Horsham, PA: Jenssen Biotech, Inc; 2011.
13. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343:1594-1602.
14. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340:253-259. (Pubitemid 29063266)
15. Breedveld FC, Weisman MH, Kavanaugh, AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54:26-37. (Pubitemid 43122183)
16. den Broeder AA, Joosten LAB, Saxne T, et al. Long term antitumour necrosis factor a monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis. 2002; 61:311-318. (Pubitemid 34257741)
17. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007; 13:1323-1332. (Pubitemid 350206841)
18. Cimzia (certolizumab pegol) package insert. Smyrna, GA: UCB Inc; 2010.
19. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [published online ahead of print December 9, 2008]. Ann Rheum Dis. 2009; 68(6):789-796.
20. Golimumab (Simponi) package insert. Horsham, PA: Janssen Biotech Inc.; 2011 Aug.
21. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003; 349:1907-1915. (Pubitemid 37409707)
22. Orencia (abatacept) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
23. Rituxan (rituximab) package insert. San Francisco, CA: Genentech, Inc, 2011.
24. Xgeva (denosumab) package insert. Thousand Oaks, CA: Amgen, Inc; 2010.
25. Cohen SB, Dore RK, Lane NE. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008; 58:1299-1309. (Pubitemid 351705919)
26. Braselmann S, Tayler V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006; 319:998-1008.
27. Weinblatt ME, Kavanaugh A, Genovese MS, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis [published online ahead of print September 22, 2010]. N Engl J Med. 2010; 363(14):1303-1312.
28. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6):762-784. (Pubitemid 351847559)